Antiandrogenic therapy can cause coronary arterial disease.
OBJECTIVE
To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer.


METHODS
We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.


RESULTS
Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.


CONCLUSIONS
Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
Chen
Kuan-Chou
KC
Graduate Institute of Medical Science, Taipei Medical University, Taiwan, China.
Peng
Chiung-Chi
CC
Hsieh
Hsiu-Mei
HM
Peng
Chiung-Huei
CH
Hsieh
Chiu-Lan
CL
Huang
Chien-Ning
CN
Chyau
Charng-Cherng
CC
Wang
Hui-Er
HE
Peng
Robert Y
RY
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood; D016633:Apolipoprotein A-II / Q000097:blood; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D017373:Cyproterone Acetate / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D000726:Androgen Antagonists; D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D015415:Biomarkers; D008076:Cholesterol, HDL; D014280:Triglycerides; D017373:Cyproterone Acetate